摘要 |
This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein G<SUP>1 </SUP>is selected from the group consisting of a, b<SUP>1 </SUP>and b<SUP>2</SUP>, and A and G<SUP>2 </SUP>are as defined in the specification; or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof. |